Benchling is a Biotechnology founded in 2012, currently valued at $6.1B. IPO Status: Pre-IPO. IPO Readiness Score: 70/100 (B-).
Benchling IPO status, timeline, valuation and S-1 filing tracker. Last updated May 2026.
| Industry | Biotechnology |
| Stage | Series F |
| IPO Status | Pre-IPO |
| Valuation | $6.1B |
| Total Funding | $260M |
| Headquarters | San Francisco, CA |
| IPO Readiness Score | 70/100 |
| Founded | 2012 |
Track Benchling IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated May 2026.
R&D cloud platform for life sciences teams to design, track, and analyze experiments.
Benchling is in the pre-IPO phase as of May 2026. With an IPO readiness score of 70/100, the company ranks among the more IPO-ready companies in the Biotechnology sector. Pre-IPO companies at this stage typically evaluate market conditions, complete board appointments, and engage underwriters before initiating the formal S-1 filing process.
Benchling is valued at $6.1B based on the most recent private market data. The company has raised a total of $260M in funding. Private market valuations are determined by the latest funding round and may differ from eventual IPO pricing, which reflects public market conditions, investor demand, and comparable company multiples at the time of listing.
Accredited investors may be able to access Benchling pre-IPO shares through secondary market platforms. These platforms facilitate private share transactions between existing shareholders (employees, early investors) and new buyers.
Risk factors: Pre-IPO investments are illiquid, carry higher risk than public market investments, and are typically restricted to accredited investors. Share availability and pricing depend on current shareholders willing to sell. TechStackIPO provides data and tracking tools but does not facilitate or recommend investments.
Benchling has an IPO readiness score of 70/100 on TechStackIPO. A high readiness score suggests IPO activity could occur within the next 1–2 years.
Benchling's last known private valuation is $6.1B. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
No. Benchling has not yet filed an S-1 registration statement with the SEC as of TechStackIPO's latest data update.
Benchling operates in the Biotechnology sector. TechStackIPO tracks multiple Biotechnology companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare Benchling against other Biotechnology companies using TechStackIPO's comparison tool.
Benchling is at the Series F stage. The company has raised a total of $260M in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
Benchling is headquartered in San Francisco, CA. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.